Upper Gastrointestinal Bleeding (UGIB)
11
3
3
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
27%
3 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (11)
PillSense Use in Anemia and Hemoccult
FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants)
A New Scoring System to Predict High-Risk Groups in Upper Gastrointestinal Bleeding
Effect of Ondansetron on Patient Tolerance, Efficacy and Endoscopist Workload in Unsedated Endoscopy for Upper Gastrointestinal Bleeding
Optimization Strategies for Blood Transfusion Protocols in the Emergency Treatment of Hemorrhagic Shock
External Validation of the Glasgow-Blatchford Bleeding Score in a Tunisian Population
Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios
Study of Patients With Drug-induced Non-variceal Upper Gastrointestinal Bleeding
Tranxemic Acid and Vitamin K Injection to Control Upper Gastrointestinal Bleeding in Cirrhotic Patients
A New Risk Score for the Emergency Department in Patients with Upper Gastrointestinal Bleeding
Evaluation of ClearPlasma in Patients With Upper Gastrointestinal Bleeding.